Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Opipramol and Baclofen for Drug Addiction
NCT03065998Phase 1Unknown
- Sponsor
- Ministry of Health
- Start
- Mar 2017
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in substance use disorder (SUD) comparing Opipramol + Baclofen with Placebo (2 arms). Primary endpoint: Decreased craving at 1 month. Status: unknown.
02
Drugs
Opiprambaclofen
03
Conditions
substance use disorder (SUD)
Beyond the preview
Go deeper on NCT03065998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03065998.